COMPANY PROFILE

GondolaBio

Explore full profile

Pioneering biotech breakthroughs to accelerate scientific and medical advancements

Palo Alto, United StatesFounded 2024Biotech & Life Sciences

Valuation $1–2.5B Last recorded · 2024

Headcount 100–500 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About GondolaBio

GondolaBio operates in the biotechnology sector, focusing on accelerating scientific and medical breakthroughs. The company serves a diverse range of clients including research institutions, pharmaceutical companies, and healthcare providers. GondolaBio's business model revolves around leveraging cutting-edge research and development to create innovative solutions that address critical medical and scientific challenges. Revenue is primarily generated through partnerships, licensing agreements, and the commercialization of proprietary technologies. The company is staffed by a multidisciplinary team of scientists, researchers, engineers, and business professionals, all dedicated to pushing the boundaries of what's possible in biotech.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2024
Headquarters: Palo Alto, United States
Employees: 85
Open positions: 9
Dealroom signal: 59.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2c
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Aug 2024	$300M	$1.2B	Aisling Capital · Patient Square Capital · Sequoia · Viking Global Investors	—
CORPORATE SPINOUTOther financing	Jul 2024	$0	—	BridgeBio	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

GondolaBio website traffic

Latest recorded traffic for GondolaBio is 6.9K monthly website visits, up 50% over the last three months. GondolaBio's team grew 28.8% over the past year.

Latest monthly visits6.9K 3-month web change+50% 1-year team growth+28.8%

Monthly website visitsOct 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Senior Manager, Patient AdvocacyPalo Alto, California, United States, Northern America, Americas · Other · Aug 25, 2026 Associate/ Director, Regulatory AffairsPalo Alto, California, United States, Northern America, Americas · Other · Aug 25, 2026 Senior Director, Clinical OperationsPalo Alto, CA · Other · Aug 24, 2026 Senior Biological Data ScientistPalo Alto, California, United States, Northern America, Americas · Data Science & Engineering · Aug 2, 2026 Director of TalentPalo Alto, CA · Human Resources · Jul 31, 2026 Director/Sr. Director, Medicinal ChemistryPalo Alto, California, United States, Northern America, Americas · Other · Jul 19, 2026 Vice President, DevelopmentSan Francisco, California, United States, Northern America, Americas · Business Development · Jul 14, 2026 Associate Director / Director, Regulatory Affairs3160, Porter Drive, Palo Alto, Santa Clara County, California, 94304, United States · Other · Jun 16, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HEHelixThe leading population genomics company working at the intersection of clinical care, research, and genomics	San Mateo, United States	Operational	614	$411M	$1B
SYSynthegoProvider of synthetic RNA solutions for CRISPR genome engineering	Menlo Park, United States	Acquired
ATAirNexis TherapeuticsPulmonary disease therapeutics for chronic obstructive pulmonary disease	Palo Alto, United States	Operational
ATAlveus TherapeuticsNext-generation obesity and metabolic disease therapies	Philadelphia, United States	Operational
BBBraveheart BioLate-stage therapeutics for hypertrophic cardiomyopathy	San Francisco, United States	Operational
CTCrystalys TherapeuticsClinical-stage biopharmaceutical developing therapies for gout	San Diego, United States	Operational
ATAntares TherapeuticsDevelopment of precision oncology therapies, utilizing acquired discovery capabilities and a validated pipeline for patient treatments	Boston, United States	Operational
CTCallio TherapeuticsBiotechnology firm advancing multi-payload ADCs for targeted cancer therapy with innovative HER2 solutions	Seattle, United States	Operational